Saturday, 3 October 2026European Markets

Euro Hits 20-Month High Against Pound as UK Budget Concerns Mount

The British pound fell 0.4% to €1.13, its lowest level since April 2023, as currency markets anticipate further weakness ahead of the UK's November 26 budget. The euro's strength against sterling creates favorable conditions for European exporters and investors with UK exposure, while analysts forecast GBP could breach $1.30.

Euro Hits 20-Month High Against Pound as UK Budget Concerns Mount
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The pound dropped to €1.13 on Tuesday, marking its weakest position against the euro in 20 months despite posting gains earlier in 2025. The 0.4% decline reflects mounting pressure on UK assets as Chancellor Rachel Reeves prepares to unveil tax increases in the November 26 budget.

"GBP is under significant pressure across the board," said Simon Phillips, Managing Director at No1 Currency. Analysts at Mizuho Bank project sterling could fall below $1.30, extending losses beyond its current $1.3086 level—down 0.5% on the day.

UK government borrowing costs climbed in parallel, with 30-year gilt yields rising 4 basis points to 5.21%, the highest since August. A Tuesday auction of inflation-linked bonds drew record demand of £69 billion for £4.25 billion in debt, surpassing March's £67.5 billion.

The currency movement benefits European businesses trading with the UK. A weaker pound makes British imports cheaper for eurozone buyers while increasing the euro value of UK revenue for continental companies. Tourism and real estate sectors see particular advantage as UK assets become more affordable for European investors.

Neil Wilson, analyst at Saxo Markets, warned of "fiscal instability risk" facing the UK government. Prime Minister Keir Starmer confronts internal party tensions as the budget approaches, with speculation around leadership challenges adding political uncertainty to economic concerns.

The pound's weakness contrasts with broader European market strength. The Stoxx 600 index reached a record 583.4 points, up 0.6%, while France's CAC 40 gained 0.7% and Germany's DAX rose 0.9%.

UK equity markets showed resilience despite currency pressure. The FTSE 100 closed at a record 9,911, up 0.1%, with intraday trading hitting 9,930. However, sterling's decline against the euro represents the largest gap in UK-eurozone exchange rates since early 2023, when post-Brexit trade adjustments were still settling.

For European manufacturers and retailers, the exchange rate shift improves competitiveness against UK rivals. German automotive exporters and French luxury goods makers gain pricing advantages in British markets, while Spanish and Italian agricultural exporters see improved margins on UK-bound shipments.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score3 source documents3 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  3. [3]News articleYahoo Finance· February 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq waver in volatile trading as AI anxiety lingers
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com